Clinical trial registry record

Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 11, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04663750
Last registry update
September 11, 2026
Status
Recruiting
Phase
Phase 3
Sponsor
King's College Hospital NHS Trust
Enrollment
210
Countries
Germany, Ireland, Netherlands, Poland, Spain, Switzerland, United Kingdom
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · SINGLE
Evidence population
Human clinical study registration
Participants
210
Population
ALL · 50 Years to 120 Years
Duration
2021-04-16 to 2028-12-01
Intervention
Pars plana vitrectomy; Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, then 2-monthly until mon…; subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls; Intravitreal 20% sulfahexafluoride (SF6) gas tamponade
Comparator
Arm B - Aflibercept monotherapy
Outcomes measured
assessment of Early Treat of Diabetic Retinopathy Study (ETDRS) letters of best-corrected visual acuity (BCVA) in the s…; Assessment of Early Treatment Diabetic Retinopathy Study (ETDRS) letter improvement in Best-Corrected Visual Acuity (BC…; Mean ETDRS BCVA — 6 and 12 months; Radner maximum reading speed — 6 and 12 months; Area of scotoma size using Humphrey Field Analyser 10-2 or equivalent — 6 and 12 month; National Eye Institute 25-item visual function questionnaire (NEI VFQ-25). composite score. — 6 and 12 months.; EQ-5D-5L with vision bolt-on score. — 6 and 12 months.; Presence/absence of subfoveal fibrosis and/or atrophy and area of fibrosis/atrophy using multimodal reading centre imag…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON